RxDoctor Payments Data

Christopher Edwards, DO

Internal Medicine · Jacksonville, FLNPI 1821307877

Payments from drug & device makers

$12,262in general payments, 2019–2025

Across 319 payments — averaging $38.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bard Peripheral Vascular, Inc.$4K
  • Johnson & Johnson$1K
  • Abbott$947
  • Boston Scientific$936
  • Medtronic$819
  • Merck$449
  • plus $4K from 47 others

What the payments were for

  • Consulting fees$2,50020%
  • Travel & lodging$2782%
  • Food & beverage$9,44577%
  • Education$390%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,262 in reported general payments places this provider in the 90th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$614,121
Medicare patients
1,414
Services billed
3,442

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban135$175,771
XareltoRivaroxaban106$145,035
EntrestoSacubitril/Valsartan36$38,700
Repatha SureclickEvolocumab29$36,931
BrilintaTicagrelor13$10,752
Valsartan169$5,191
Metoprolol Succinate248$3,609
Rosuvastatin Calcium204$3,078
Carvedilol213$2,378
Atorvastatin Calcium120$2,099
ClopidogrelClopidogrel Bisulfate167$1,876
Nifedipine ErNifedipine44$1,461
Amlodipine Besylate200$1,365
Ezetimibe71$1,164
Spironolactone110$1,163

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$318$175,771135 claims
Johnson & JohnsonXarelto$1,085$145,035106 claims
NovartisEntresto$286$38,70036 claims
AstraZenecaBrilinta$16$10,75213 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Jacksonville

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →